Skip to content


Mitchell Mutz, PhD, is an accomplished biotech serial entrepreneur, venture investor, and inventor.  Since 2021, he has served as Entrepreneur Partner at Vivo Capital. Mitchell focuses on early stage investment opportunities in therapeutics. He is currently on the board of Epi Biologics. Prior to joining Vivo, Mitchell was Senior Investment Director at the Roche Venture … Continued


Samuel Bjork is a Partner at Digitalis Ventures, where he leads the firm’s life sciences practice.  He has served as a director or observer on the boards of multiple companies, including Elemental Machines, EpiBiologics, Good Therapeutics (acquired by Roche), Nuvig Therapeutics, PetMedix (acquired by Zoetis), T-Therapeutics, and Terray Therapeutics, among others. Prior to Digitalis, Samuel was a member … Continued


Nicholas Walrod is a Managing Partner with American Century Investments’ Private Investments team. He brings 20 years of experience as an investor, board member, and strategic partner to the service of ground-breaking companies in the life sciences and climate solutions. Before joining American Century, Nick co-founded 3×5 Partners, a venture-capital investment firm. Previously, Nick sourced and … Continued


Monique is a Senior Investment Director at the Roche Venture Fund. Former roles include serving as the Chief Operating Officer at Inthera Bioscience AG, a previous Director position at Roche Venture Fund from 2009 to 2018, and a principal position with BankInvest’s BioMedical Ventures Group in Copenhagen. In addition, Monique’s background includes several years in … Continued


John has three decades of drug development and investing experience in life sciences. He joined RiverVest in 2008 and focuses on early-stage biotechnology investments. Currently, John serves on the boards of Allakos, Inc. (IPO), OncoResponse, Inc., Bonum Therapeutics, Arch Oncology, Inc., and Adarza Biosystems, Inc. He previously served on the boards of Lumena Pharmaceuticals, Inc. … Continued


Karl D. Handelsman is the founder and Managing Partner, Codon Capital, and a key contributor and builder in the US biotech innovation ecosystem. Through his network and leadership, he drives Codon Capital to intensely focus on the best biotech targets for investments. The key criteria are the team, the technology, and the investment syndicate. Karl … Continued


Dr. John Mulligan is a scientist and executive with 30 years of experience in research management, drug discovery, technology innovation and company formation.  He was the Founder and CEO of Good Therapeutics until it was acquired by Roche in 2022.  Prior to Good he founded Glycostasis, where he invented a glucose-responsive insulin technology and sold … Continued